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Despite the clinical relevance of latent HIV-1 infection as a block to HIV-1 eradication, 3 
the molecular biology of HIV-1 latency remains incompletely understood.  We recently 4 
demonstrated the presence of a gatekeeper kinase function that controls latent HIV-1 infection.  5 
Using kinase array analysis we here expand on this finding and demonstrate that the kinase 6 
activity profile of latently HIV-1 infected T cells is altered relative to uninfected T cells.   A 7 
ranking of altered kinases generated from these kinome profile data predicted PIM-1 kinase as 8 
a key switch involved in HIV-1 latency control.  Using genetic and pharmacologic perturbation 9 
strategies, we demonstrate that PIM-1 activity is indeed required for HIV-1 reactivation in T cell 10 
lines and primary CD4 T cells.  The presented results thus confirm that kinases are key 11 
contributors to HIV-1 latency control.  In addition, through mutational studies we link the 12 
inhibitory effect of PIM-1 inhibitor IV (PIMi IV) on HIV-1 reactivation to an AP-1 motif in the 13 
CD28 responsive element of the HIV-1 long terminal repeat (LTR).  The results expand our 14 
conceptual understanding of the dynamic interactions of the host-cell and the latent HIV-1 15 
integration event and position kinome profiling as a research tool to reveal novel molecular 16 
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Eradication of the latent HIV-1 reservoir is considered a major requirement towards the 3 
development of a cure for HIV-1 infection.  Therapeutically induced reactivation of latent HIV-1 4 
infection events will be an essential first step in this process.  At present, it is widely assumed 5 
that HIV-1 latency is the result of a special restrictive histone composition or a unique restrictive 6 
chromatin environment established at the latent viral promoter.  This idea has guided the 7 
majority of the therapeutic efforts to eradicate the latent HIV-1 reservoir.  Histone deacetylase 8 
inhibitors (HDACi) such as valproic acid, or more recently vorinostat/SAHA, were used in an 9 
attempt to relieve this proposed chromatin-mediated transcriptional restriction and trigger 10 
system-wide HIV-1 reactivation (1-4).  In one of these studies the authors could demonstrate 11 
vorinostat-promoted induction of viral RNA in the treated patients (4).  Other reports, including a 12 
recent study from the Fauci/Chun laboratory using ex vivo patient material could not confirm that 13 
HDACi trigger HIV-1 reactivation (5-8).  Most recently the Siliciano team tested the efficacy of 14 
17 HDAC inhibitors as HIV-1 reactivating agents in latently HIV-1 infected primary resting CD4+ 15 
T cells transduced with the anti-apoptotic Bcl-2 gene (9).  None of the HDAC inhibitors triggered 16 
efficient reactivation relative to CD3/CD28 mAb treatment during short-term treatment 17 
experiments, but some exhibited good HIV-1 reactivation efficacy in long-term treatment 18 
experiments.  Notably, in these and previously published experiments, reactivated infection 19 
events reverted to a latent state when the drugs were removed from culture (10).  While the 20 
value of HDAC inhibitors as HIV-1 reactivating agents in a therapeutic setting thus remains 21 
unclear, it is becoming increasingly evident that drugs that can complement or replace HDACi-22 
based therapy approaches are needed to achieve the goal of HIV-1 eradication.  A more 23 
comprehensive understanding of the dynamic interaction between the host-cell and the latent 24 
virus that extends beyond the relatively static current model of latent HIV-1 infection will be 25 
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 4 
In support of the idea that many molecular mechanisms that control latent HIV-1 1 
infection have yet to be identified, we recently reported that latency control starts at the level of 2 
kinase activity.  We demonstrated the presence of a kinase function that acts as a master switch 3 
to control latent HIV-1 infection even in the presence of high levels of induced NF-κB activity, 4 
which was present in latently infected T cell lines and primary CD4 T cells (11).  Additional 5 
evidence for a role of specific transcription factors in latency control comes from our observation 6 
that naturally occurring variations of the AP-1 motif in the CD28RE of the HIV-1 LTR influence 7 
the efficacy of latency establishment (12).  These data suggest that latent infection is controlled 8 
by dynamic, bi-directional interactions of the virus with the host-cell at the kinase and 9 
transcription factor level.  To this end, latent HIV-1 infection can be viewed as a normal gene 10 
regulation phenomenon.  Once integrated, HIV-1 acts as a cellular gene controlled by its 11 
promoter (LTR), which is structurally similar to promoters of cellular genes such as interleukin-2 12 
(IL-2), TNF-α, or the IL-2 receptor α chain (CD25).  It is worth noting that these genes, just as 13 
latent HIV-1 infection, are not expressed in CD4+ memory T cells, which are the primary cellular 14 
host of latent HIV-1 infection.  Beyond the demonstration that these genes are controlled by 15 
defined kinase activities and a defined down-stream transcription factor composition, there are 16 
other important reported similarities between cellular gene expression control and latent HIV-1 17 
infection.  For example, paused RNA polymerase II complex (RNAP II), which is found at the 18 
promoters of non-expressed, but inducible genes (13-16), has also been found associated with 19 
the latent LTR promoter (17-20).   20 
Other similarities have been found at the level of nucleosome positioning.  Recently, 21 
Rafati et al. reported that for latent HIV-1 infection events the two nucleosomes that are found at 22 
the LTR are actively re-positioned away from their predicted DNA binding sites as a function of 23 
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 5 
transcription factors to the LTR (21).  Similar findings have been reported earlier for many 1 
inactive, but inducible cellular promoters (for recent reviews see (22, 23)).  2 
We here expand on our findings that kinases play a key role in the control of latent HIV-1 3 
infection and HIV-1 reactivation.  Using kinome profiling, we demonstrate that at the level of 4 
their kinase activity profile latently HIV-1 infected T cells phenotypically differ from uninfected 5 
cells.  We demonstrate that as predicted by the protein interaction network (PIN) map generated 6 
from these data, PIM-1 kinase is involved in HIV-1 reactivation in T cell lines.  This finding can 7 
be directly transferred to latent infection in primary T cells.  Lastly, we provide experimental 8 
evidence that PIM-1 must act through transcription factors that bind to an AP-1 motif in the 9 
CD28RE of the latent HIV-1 LTR, linking kinase activity directly to the available transcription 10 
factor composition.  In summary, our findings provide additional evidence for a key role of 11 
kinase control in HIV-1 latency and establish kinome profiling as a research tool to identify novel 12 
drug targets for HIV-1 reactivation.  13 
 14 
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 6 
MATERIALS AND METHODS  1 
 2 
Cell culture, plasmids and reagents.  All T cell lines were maintained in RPMI 1640 3 
supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% 4 
heat inactivated fetal bovine serum. The latently HIV-1 infected CA5 and EF7 T cells were 5 
generated using a NL4-3-based GFP reporter virus (NLENG) (11, 24).  Each of these cell lines 6 
contains a single integration event within an actively expressed host-gene.  In CA5 T cells, the 7 
virus is integrated in the same transcriptional orientation as the host gene, while in EF7 T cells, 8 
the latent virus is integrated in the converse-sense orientation.  J2574 reporter T cells are 9 
described previously (12).  Briefly, J2574 cells were generated by infecting Jurkat T cells with a 10 
HIV-1 LTR-GFP-LTR construct (p2574) and then selecting for a population that expresses no 11 
GFP in the absence of infection, but expresses GFP upon Tat-transduction or HIV-1 infection.  12 
The J2574 T cell population holds at least 50,000 founder cells with different integration sites.  13 
Fetal bovine serum (FBS) was obtained from HyClone (Logan, UT) and was tested on a panel 14 
of latently infected cells to assure that the utilized FBS batch did not spontaneously trigger HIV-15 
1 reactivation (25, 26).  The phorbol ester, 13-phorbol-12-myristate acetate (PMA), was 16 
purchased from Sigma.  Recombinant human TNF-α was obtained from R&D Systems 17 
(Minneapolis, MN). AS601245 and PIMi IV (CAS 477845-12-8) were purchased from 18 
Calbiochem (Billerica, MA). Anti-CD25 antibody was purchased from BD Biosciences-19 
Pharmingen (San Jose, CA).   20 
 21 
Latent HIV-1 infection of primary T cells.  Latently infected cultured central memory CD4+ T 22 
cells were prepared from primary naïve cells as previously described (7, 27).  Briefly, peripheral 23 
blood mononuclear cells were obtained from de-identified healthy donors. Naïve CD4+ T cells 24 
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 7 
Biotec, Auburn, CA). The purity of the sorted population was always higher than 95% with a 1 
phenotype of CD4+CD45RA+CD45RO-CCR7+CD62L+CD27+.  Naïve CD4+ T cells were primed 2 
with beads coated with anti-CD3 and anti-CD28 antibodies (Dynal/Invitrogen, Carlsbad, CA).  3 
Proliferating cells were expanded in medium containing 30 IU/mL rIL-2, replacing media and IL-4 
2 every 2 days.  DHIV viruses were produced by transient transfection of HEK293T cells by 5 
calcium phosphate–mediated transfection (7, 27). To normalize infections, p24 was analyzed in 6 
virus-containing supernatants by enzyme-linked immunosorbent assay (ELISA; ZeptoMetrix, 7 
Buffalo, NY). Cells were infected by spinoculation: 1x106 cells were infected with 500 ng/ml p24 8 
during 2 hours at 2,900 rpm and 37°C in 1 ml. 9 
 10 
Western blotting. Cells were harvested by centrifugation, washed once with PBS buffer and 11 
lysed in RIPA buffer (Cell Signaling, Danvers, MA) according to the manufacturer’s instructions.  12 
Protein concentration of the lysates was determined by the Bicinchoninic Acid (BCA) method 13 
according to the manufacturer’s recommendations (Pierce, Rockford, IL).  About 20 - 40 µg of 14 
protein per sample was separated on pre-casted 10% Mini Protean TGX gels (BioRad, 15 
Hercules, CA) and subsequently transferred to a PVDF membrane using an iBlot gel transfer 16 
system (Invitrogen, Carlsbad, CA).  Western blot was performed according to standard 17 
protocols. IκB protein (or tubulin as a control) was detected with specific monoclonal antibodies 18 
(Cell Signaling, USA). A horseradish peroxidase conjugated mouse anti-rabbit polyclonal 19 
antibody (Cell Signaling) was used as a secondary antibody. The blot was developed using the 20 
western lightning ultra chemiluminescent substrate from Perkin Elmer, Inc. (USA) and detected 21 
in an EpiChemi3 Darkroom (UVP BioImaging System, Upland, CA).   22 
 23 
TransAM assays for NF-κB.  NF-κB p50 and p65 activity in nuclear extracts of cells were 24 
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 8 
the manufacturer’s instructions.  TransAM assays quantify the ability of activated NF-κB to bind 1 
to a NF-κB consensus sequence in solution, with a 5- to 10-fold higher sensitivity than gel-shift 2 
assays.   3 
 4 
BioPlex analysis of cytokine expression.  PBMCs were generated as previously described 5 
(11).  T cells were stimulated in the presence or absence of the respective inhibitors using 3 6 
µg/ml PHA-L and culture supernatants were harvested after 24 hours.  Cytokine expression was 7 
determined using MilliPlex kits for IL-2, IL-4, IL-6, IL-8, IL17 and IFN-γ (Millipore). 8 
 9 
Flow cytometry.  Infection levels in the cell cultures were monitored by flow cytometric (FCM) 10 
analysis of GFP expression. FCM analysis was performed on a GUAVA EasyCyte (GUAVA 11 
Technologies, Inc., Billerica, MA), a FACSCalibur or a LSRII (Becton Dickinson, Franklin Lakes, 12 
NJ).  Cell sorting experiments were performed using a FACSAria™ Flow Cytometer (Becton 13 
Dickinson).  Data analysis was performed using either CellQuest (Becton Dickinson) or GUAVA 14 
Express (GUAVA Technologies, Inc.) software. 15 
 16 
Kinomic analysis. Kinomic profiling of Jurkat, CA5, and EF7 cellular lysates was conducted in 17 
the UAB Kinome Core using the PamStation® 12 platform (PamGene, ‘s-Hertogenbosch, The 18 
Netherlands).  This platform consists of a high throughput peptide microarray system analyzing 19 
either 144 individual tyrosine phosphorylatable peptides on the Protein Tyrosine Kinase (PTK) 20 
array or 144 serine and threonine kinase phosphorylatable peptides on the Serine-Tyrosine 21 
Kinase (STK) array. All peptides are composed of 12-15 amino acids that are imprinted onto an 22 
aluminum oxide matrix allowing exposure to kinases to measure activity in lysates that are 23 
pumped through these peptide rich matrices. Phospho-specific FITC conjugated antibodies 24 
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 9 
captured via a computer controlled charge coupled device (CCD) camera with kinetic image 1 
capture over time and over multiple exposures.  For PTK analysis 10µg of each quantified 2 
lysate was mixed to a total of 28µl in deionized H20 (dH20) with 4µl of 10xPK/Abl kinase buffer 3 
(New England Biolabs), 4µl 10xBSA solution and 0.4µl 1M Dithiothreitol (DTT; Fluka).  4 
Immediately prior to loading onto the array 0.3µl of the FITC conjugated PY20 phosphotyrosine 5 
antibody (PamGene) was added along with 4µl of a freshly prepared 4mM ATP solution to the 6 
lysate mixture.  Lysate solution was pipette mixed and quickly loaded at 35µL per array after the 7 
blocking step with 2% BSA was completed. During the assay, active kinases in the lysate 8 
phosphorylate specific peptides on the array that are detected by quantitating FITC intensity for 9 
each spot on each array using a constant 50 ms camera exposure time captured every 6 10 
seconds over the course of the reaction (60 minutes). Evolve software (PamGene) generates 11 
kinetic reaction curves for each phosphopeptide probe with the slope referred to as Initial 12 
Velocity (vINI), and end of reaction images labeled as ‘End-Level’. An additional set of images is 13 
captured following a wash step (‘Postwash’) at 10, 20, 50, 100 and 200ms camera exposures to 14 
provide an integrated measure of peptide phosphorylation (S100).  For STK analysis, 1µg of 15 
each quantified lysate was mixed to a total volume of 34.5µl in dH20 with 4µl of 10xPK and 1.6µl 16 
of 100xBSA solution (PamGene). Immediately prior to loading onto the array 1µl of a freshly 17 
prepared 4mm ATP solution was added. Lysate solution was pipette mixed quickly and loaded 18 
at 35µl per array after the blocking step was completed by the PamStation®12.  For each chip 19 
(4 arrays) 1.01µl of the stock STK primary antibody mixture (PamGene) was mixed with 13.2µl 20 
10% BSA in phosphate buffered saline (PBS), 0.35µl of the STK FITC-conjugated secondary 21 
antibody (PamGene) and brought up to a volume of 132µl per chip (4 arrays). This mixture was 22 
gently pipette mixed, and applied at 30µl per array, and the PamStation® STK protocol was 23 
continued. Digital images were captured only as ‘Postwash’ pictures at 10, 20, 50, 100 and 24 
200ms to allow optimization of signal level quantification.  An integrated signal level (S100) was 25 
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 10 
between samples were performed using BioNavigator software version 5 (PamGene) to identify 1 
significantly different phosphopeptides (p<0.05 by t-test). Upstream kinases were identified by 2 
scoring potential kinases based on their prevalence in the top ten kinase scoring lists for each 3 
phosphopeptide as mapped in the Kinexus upstream kinase database (www.phosphonet.ca). 4 
Furthermore, protein interaction networks (PIN) were generated by uploading the peptide 5 
substrate information into the MetaCore knowledge base (Thomson Reuters). 6 
 7 
 8 
Targeting PIM-1 expression. shRNA vectors targeting PIM-1 gene expression were generated 9 
using pSilencer 5.1-U6 Retro vector from Ambion (Austin, TX).  In U6/shRNA PIMpos380 10 
(shPIM#10) we inserted GATCTCTTCGACTTCATCATTCAAGAGATGATGAAGTCGAAGAG-11 
ATCTTTTTT to target PIM-1 expression.  In U6/shRNA PIMpos785 we inserted GTGTCAG-12 
CATCTCATTAGATTTCAAGAGAATCTAATGAGAT-GCTGACATTTTTT to target PIM-1 13 
expression (shPIM#22).  Latently HIV-1 infected CA5 T cells were retrovirally transduced with 14 
these constructs, puro-selected and cloned. Overexpression of PIM-1 was achieved by retroviral 15 
transduction of latently HIV-1 infected CA5 T cells with a pMSCV-PIM-1 expression vector. 16 
 17 
Statistics.  Where indicated, experiments were performed at least in triplicates.  Experimental 18 
results were then presented as mean values and the standard deviation is indicated as error 19 
bars as a descriptor of the variation from the mean.  Where indicates, Student’s T-test was 20 
performed to evaluate the significance of possible drug effects by comparing two experimental 21 
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Kinome profiling reveals PIM-1 as a kinase involved in latent HIV-1 infection.  Previous 3 
studies from our laboratories provided evidence for a key role of kinase activity in the control of 4 
latent HIV-1 infection (11).  To develop a comprehensive understanding of how kinases play a 5 
role in latent HIV-1 infection, we performed kinome profiling experiments.  Using kinome array 6 
analysis, we determined the baseline kinase activity profile of parental Jurkat T cells in 7 
comparison to the kinase activity profile of two molecularly well defined, latently HIV-1 infected 8 
Jurkat T cells clones with single integration events, CA5 and EF7 T cells (24).  In these 9 
experiments, cell lysates from Jurkat, CA5 and EF7 T cells were loaded on high throughput 10 
peptide microarray chips holding either 144 individual phosphorylatable peptides specifically 11 
recognized by tyrosine kinases or 144 phosphorylatable peptides that are specifically 12 
recognized by serine/threonine protein kinases. Peptides with the greatest increase in 13 
phosphorylation in the latently HIV-1 infected cells relative to the parental Jurkat T cells were 14 
selected for upstream kinase analysis as described in Materials and Methods.  In both latently 15 
HIV-1 infected cells, CA5 and EF7 T cells, PIM-1 was the highest scoring kinase relative to the 16 
parental Jurkat T cells (see Table 1).  In addition, we also found that PIM-1 was the highest 17 
scoring kinase in J89GFP T cells, the first latently HIV-1 infected GFP-reporter cell line we 18 
established (25).  19 
A PIM-1 centric shortest paths PIN map derived from these experiments that describes 20 
likely relevant interactions of PIM-1 with other proteins is depicted in Figure 1.  Among other 21 
factors, PIM-1 is directly linked to NF-κB, as well as to Cyclin Dependent Kinase 2 (CDK2).  22 
CDK2 has recently been demonstrated to be important for HIV-1 transcription by regulating the 23 
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 12 
PIN to these factors can be viewed as a descriptor of the importance of PIM-1 in the context of 1 
HIV-1 latency. 2 
While we demonstrate in the following that PIM-1 plays an important role in HIV-1 3 
latency control, the results also have more general implications.  Among the top 10 kinases with 4 
increased activity, not only PIM-1, but also MAPKAPK3 and PIM-3 were found altered in all 5 
three tested cell lines, suggesting that latently HIV-1 infected T cells are phenotypically altered, 6 
and that these changes are essential to latency control. 7 
 8 
PIM inhibitor IV inhibits HIV-1 reactivation in CA5 T cells.  Supporting the idea that PIM-1 9 
plays a role in HIV-1 latency control, we had identified 4-(3-(4-Chlorophenyl)-2,1-benzisoxazol-10 
5-yl)-2-pyrimidinamine or PIM-1 inhibitor IV (PIMi IV) as an inhibitor of HIV-1 reactivation during 11 
a drug screening campaign (Figure 2). PIMi IV prevented TNF-α induced HIV reactivation in 12 
CA5 T cells with an IC50 of 3µM, but was somewhat less potent to inhibit PMA induced 13 
reactivation (Figure 2B).  At 10 µM concentration, PIMi IV was still ~70% effective in preventing 14 
PMA induced HIV-1 reactivation, as determined by flow cytometric analysis using the latently 15 
HIV-1 infected CA5 T cells.  Optimal pretreatment time prior to stimulation was found to be 6 16 
hours. In all experiments, addition of PIMi IV at the utilized concentrations did not increase cell 17 
death relative to cell death seen in control or stimulated conditions in the absence of the 18 
inhibitor.  The stimulus-dependent differences in the inhibitory capacity of PIMi IV indicated that 19 
the inhibitor could exhibit some selectivity for kinase pathways that are stimulated by TNF-α.  20 
Other commercially available PIM inhibitors were less efficient and required longer pretreatment 21 
periods prior to display their inhibitory activity on HIV-1 reactivation.  Data for PIMi II-mediated 22 
inhibition of HIV-1 reactivation are presented in Figure 2C.  Optimal pretreatment time here was 23 
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 13 
inhibitor that targets the active site of the enzyme, while all other available PIM inhibitors, 1 
including PIMi II, target the ATP-binding site of PIM-1 (31). 2 
While PIMi IV prevented HIV-1 reactivation, the inhibitor had no effect on active HIV-1 3 
expression. We titrated the compound on two chronically actively infected GFP reporter T cell 4 
lines, JNLG T cells (32) and CUCY T cells (33).  Four day post addition of the compound we 5 
determined changes in GFP mean channel fluorescence intensity (MFI), which would be 6 
indicative of an inhibitory effect of the compound on HIV-1 expression using flow cytometry.  7 
Even at 10 µM, PIMi IV did not show any inhibitory effect on HIV-1 expression in either cell line.  8 
The data for JNLG cells are shown in Figure 2D.  We have previously demonstrated that 9 
addition of Ro24-7249, a compound previously tested as a HIV-1 transcription inhibitor, causes 10 
a decrease in GFP MFI >80% in these cells (32, 33).  Again, addition of PIMi IV at the utilized 11 
concentrations did not increase cell death relative to cell death seen in control conditions in the 12 
absence of the inhibitor. Thus, PIMi IV selectively inhibits HIV-1 reactivation without affecting 13 
active HIV-1 expression. 14 
These results suggest that the presence of PIM-1 is essential for a stimulus to trigger 15 
HIV-1 reactivation.  If this is correct, overexpression of PIM-1 will facilitate reactivation, as PIM-1 16 
is an autophosphorylating protein that is regulated primarily at the level of expression.  Indeed, 17 
overexpression of PIM-1 in the latently infected CA5 and EF7 T cells did not trigger HIV-1 18 
reactivation. As gene regulation in T cells (and other cells) generally occurs within a buffered 19 
system with multiple and often redundant levels of molecular, it is not to be expected that every 20 
manipulation of a single factor of necessity results in an immediate phenotypic effect.  However, 21 
PIM-1 overexpression facilitated reactivation by a second activating stimulus, demonstrated 22 
here for the PKC agonist, bryostatin, a clinically relevant HIV-1 reactivating agent that is 23 
currently in clinical trials as an anti-cancer compound (Figure 2E) (34-36).  Following PIM-1 24 
overexpression, to achieve the same level of HIV-1 reactivation, the concentration requirements 25 
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 14 
transcriptional stability of the integrated latent HIV-1 infection event.  Similar effects were 1 
observed in EF7 T cells, confirming the idea that PIM-1 presence is one key requirement to 2 
trigger HIV-1 reactivation.   3 
 4 
PIM-1 knockdown affects HIV-1 reactivation. Conversely, knockdown of PIM-1 should 5 
increase the concentration requirement for an activating stimulus to trigger HIV-1 reactivation.  6 
To test this idea, we transduced CA5 T cells with two different PIM-1 specific shRNA vectors. A 7 
cloning and puromycin selection step was found essential, as knockdown of PIM-1 affected cell 8 
growth rates and low-level PIM-1 expressing cells were quickly overgrown in the cell culture.  9 
Consistent with the data obtained using pharmacologic PIM-1 inhibitors, shRNA#10-induced 10 
PIM-1 knockdown reduced achievable reactivation levels in the various generated CA5-11 
PIMshRNA clones.  Similar results were obtained for experiments using a second PIM-1-12 
specific shRNA#22 (Figure 2F).  Control transductions with a scrambled shRNA did not show 13 
any significant changes in the TNF-α-induced HIV-1 reactivation response.  The observed 14 
inhibitory effect of PIM-1 shRNA was overall less pronounced than the inhibitory effect of 15 
PIMi IV.  This could be explained by clonal effects or by the reported ability of PIM-2 and PIM-3 16 
to at least partly compensate for PIM-1 activity that is specifically targeted by the shRNA 17 
approach.  In contrast, pharmacological PIM inhibitors, at the utilized concentrations, will at least 18 
partially inhibit other PIM kinases and prevent functional compensatory escape. 19 
 20 
PIMi IV prevents HIV-1 reactivation in latently infected primary CD4 T cells.  The primary 21 
goal of these studies is to provide additional evidence for the concept that a regulated kinase 22 
activity network exerts a gatekeeper function for HIV-1 latency control and this control level 23 
even supersedes induced NF-κB activity effects.  As we develop the idea of a kinase 24 
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 15 
whether even details, such as particular kinase activities, can be transferred from our T cell line 1 
models to latency control in primary CD4 T cell models. We thus tested whether PIMi IV would 2 
also inhibit reactivation of latent HIV-1 infection in a primary CD4 T cell model of HIV-1 latency.  3 
For this purpose, latently HIV-1 infected cultured central memory CD4 T cells were prepared 4 
from primary naïve CD4 T cells as previously described (7, 27).  Figure 3A shows the results of 5 
two independent experiments.  Over active background infections at 1% and 0.5%, antibody-6 
mediated CD3/CD28 co-stimulation revealed latent HIV-1 reservoirs of 35% and 70%, 7 
respectively.  Cyclosporin A (CsA), as a control inhibitor abrogated CD3/CD28-mediated HIV-1 8 
reactivation to 2% or 9%, respectively. In the presence of PIMi IV (10µM) HIV-1 reactivation was 9 
reduced to 14% or 37%, respectively.  PIMi IV at 10 µM neither affected activation-induced blast 10 
transformation (data not shown), nor did it affect upregulation of CD25 (Figure 3B), a primary T 11 
cell activation marker (IL-2 receptor α-chain).  Therefore, PIMi IV is capable of selectively 12 
reducing HIV-1 reactivation in latently infected primary CD4 T cells without affecting overall T 13 
cell activation.  Following the identification of the JNK inhibitor AS601245 as an inhibitor of HIV-14 
1 reactivation (11), PIMi IV is the second kinase inhibitor that we identified in Jurkat cell-based T 15 
cell line models that also exerts activity in primary CD4 T cell models of HIV-1 latency.  This 16 
may not come as a surprise, as Jurkat T cells for decades have served as one of the most 17 
reliable models for T cell signaling research. 18 
 19 
Selective effect of PIMi IV on induced cellular gene expression.  To provide additional 20 
evidence that PIMi IV specifically acts on latent HIV-1 infection, we next explored the ability of 21 
PIMi IV to regulate induced cellular gene expression.  For this purpose, we stimulated peripheral 22 
blood mononuclear cells from three independent donors with PHA-L, either in the presence or 23 
the absence of PIMi IV, and determined IL-2, IL-4, IL-6, IL-8, IL-17, and IFN-γ induction.  For 24 
these cytokines, we observed differences in the dynamic range of the effects between the 25 
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 16 
induction to different degrees.  In contrast, the presence of PIMi IV amplified induced IL-4 and 1 
somewhat IL-17 expression.  Induction of IL-8 and IFN-γ was not affected by the presence of 2 
PIMi IV (Figure 4).  Again, these data provide experimental evidence that the kinase activity 3 
targeted by PIMi IV controlled latent HIV-1 infection without impairing overall T cell function or 4 
acting as a non-specific inhibitor of transcription. These data further imply that NF-κB activation 5 
is not affected, as induction of all tested genes is NF-κB regulated.  Lastly, the data suggest that 6 
PIMi IV acts as a selective transcriptional inhibitor that likely is only active in the context of a 7 
particular transcription factor binding site composition of a particular promoter.  8 
 9 
PIMi IV suppresses HIV-1 reactivation despite high levels of induced NF-κB activity.  All of 10 
the utilized HIV-1 reactivating stimulators, TNF-α, PMA, or bryostatin for T cell lines and PHA-L 11 
or αCD3/CD28 mAb combinations for primary CD4 T cells, converge in the NF-κB pathway.  12 
With the exception of AS601245, other reported inhibitors of HIV-1 reactivation exerted their 13 
inhibitory function on HIV-1 reactivation by preventing NF-κB activation (37). Our data on the 14 
selective effect of PIM IV on cytokine induction suggested that NF-κB activation and 15 
translocation may not be the target of PIMi IV activity.  Also, if PIMi IV would affect NF-κB 16 
translocation, active HIV-1 expression should be inhibited by PIMi IV, but this was not the case 17 
(Figure 2D).  18 
  To formally demonstrate that PIMi IV prevents HIV-1 reactivation without inhibiting NF-19 
κB activation, we stimulated the latently HIV-1 infected CA5 reporter T cells with TNF-α, either 20 
in the presence or absence of optimal inhibitory concentrations of PIMi IV (10 µM), and initially 21 
determined the kinetic NF-κB p50 and p65 activity profiles over the first 4 hours of stimulation.  22 
Nuclear cell extracts from the cultures were generated at various time points for up to 4 hours 23 
post-stimulation and NF-κB activity, as measured by the TransAM assay (DNA binding), was 24 
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 17 
for large inhibitory effect exerted by PIMi IV (Figure 5A).  When we compared peak NF-κB 1 
activity in the three independent experiments in the presence or absence of 10 µM PIMi IV at 60 2 
minutes post activation, we again, did not detect any difference between the experimental 3 
conditions that indicated that the inhibitory effect of PIMi IV would be the result of NF-κB 4 
inhibition (Figure 5B). In these experiments, TNF-α stimulation triggered ~70% reactivation of 5 
latent HIV-1 infection in the control cultures, but reactivation was fully suppressed in the cultures 6 
that were treated with PIMi IV (10 µM) (Figure 5C).  In line with these data, no differences in the 7 
kinetic IκB expression profiles of TNF-α-induced control or PIMi IV treated T cells were 8 
observed during this time frame (Figure 5D).  PIMi IV thus targets a kinase activity that controls 9 
latent HIV-1 infection in the presence of high levels of NF-κB activity.  The identification of a 10 
second kinase inhibitor, PIMi IV (in addition to AS601245), that prevents HIV-1 reactivation in 11 
the face of high levels of NF-κB activity confirms our recent findings that suggest a level of 12 
molecular control by a kinase network that supersedes the effect of NF-κB on latent HIV-1 13 
infection (11).   14 
 15 
PIMi IV effect is dependent on the CD28RE motif of the HIV-1 LTR.  A remarkable property 16 
of PIMi IV was its differential effect on the induced expression of various cytokines.  Beyond the 17 
realization that PIMi IV does not interfere with general T cell activation these results are 18 
interesting in the context that IL-2, IL-4, IL-6, and IL-8 have all been reported to be controlled at 19 
the transcriptional level by a CD28 responsive element (CD28RE), yet, functional disparity 20 
toward mitogenic stimulation for some of these promoters (IL-2, IL-6, IL-8) and HIV-1 has been 21 
previously reported (38, 39).  This raises the possibility that PIMi IV activity, which differentially 22 
acts on mitogen-induced activation of these genes, may actually be functionally linked to down-23 
stream events that interact with the CD28RE in the HIV-1 LTR (Figure 6A).  As we recently 24 
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 18 
region -1 to -147 relative to the transcriptional start site, which includes the CD28RE, greatly 1 
varied in their ability to establish latent HIV-1 infection, these viral constructs provide a tool to 2 
test this hypothesis (12).  Differential effects of PIMi IV on reactivation of latent infection events 3 
established with these viral constructs can link PIMi IV effects to the transcription factor binding 4 
site composition of the LTR and thus suggest that PIMi IV will affect transcription factors that 5 
interact with the respective LTR sequence. 6 
 We thus generated a panel of latently infected J2574 reporter T cells using some of 7 
these previously used HIV LAI-based viral vectors.  HIV LAI-A is a viral construct in which the 8 
region -1 to -147 relative to the transcriptional start site of the parental HIV LAI (subtype B; for 9 
clarity referred to as LAI-B) was replaced by the corresponding region of a prototypic subtype A 10 
virus (40).   In our experimental models this virus established up to 5-fold higher levels of latent 11 
infection (12).  The generated latently infected reporter T clones are henceforth referred to as 12 
Jlat-B or Jlat-A, respectively.  All latent infection events in the selected T cell clones were fully 13 
reactivatable by NF-κB activating compounds (PMA, prostratin, TNF-α), but as in other latently 14 
infected T cells that we previously established, latent infection was refractory to treatment with 15 
histone deacetylase inhibitors (NaBu, trichostatin A or valproic acid) (41, 42).  The cell-16 
differentiating agent HMBA triggered some level of HIV-1 reactivation, as did the bi-modal agent 17 
SAHA/vorinostat, which acts as a cell-differentiating agent and as a HDAC inhibitor (data not 18 
shown) (41, 42).   19 
When PIMi IV was titrated on several latently infected Jlat-B and Jlat-A clones prior to 20 
stimulation with PMA, PIMi IV inhibited reactivation of latent LAI-B infection, it only exerted a 21 
marginal inhibitory effect on reactivation of latent HIV LAI-A infection (Figures 6B).  To ensure 22 
that the observed failure of PIMi IV to inhibit LAI-A reactivation was not due to some unidentified 23 
clonal effects, we next tested the inhibitory effect of PIMi IV on PMA-induced reactivation in 24 
populations of either latently LAI-B or LAI-A polyclonally infected J2574 T cells.  These 25 
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 19 
inhibited HIV-1 reactivation in the latently LAI-B infected J2574 T cell population, but not in the 1 
latently LAI-A infected T cell population (Figure 6C).    2 
As LAI-A and LAI-B are syngeneic with the exception of the extended core/enhancer 3 
promoter region from -1 to -147, we focused on this region to investigate whether a specific 4 
transcription factor-binding motif would be responsible for this phenotype.  Using a series of 5 
viruses with targeted LTR mutations that were used to establish latently infected T cells, we 6 
narrowed down the LTR region that is important for the inhibitory effect of PIMi IV to the 25nt 7 
upstream of the NF-κB element (12).  This is the same region that we found to govern HIV-1 8 
latency establishment and which holds the AP-1 motif of the CD28RE responsible for this effect 9 
(12).  To test whether the AP-1 site sequence would be responsible for the selective effect of 10 
PIMi IV on reactivation, we used a NL4-3 virus in which we had mutated two of three 11 
nucleotides downstream of the 4nt AP-1 site to generate the subtype A specific 7nt AP-1 site.  12 
Other than the two nucleotides NL4-3 wt and the resulting NL-7nt/AP-1 were syngeneic, 13 
including the sequence of the NF-κB element (Figure 6A).  Moreover, the two nucleotide 14 
mutation did not attenuate the ability of NL-7nt/AP-1 to drive expression or viral replication ((12) 15 
and data not shown).  Using NL4-3 wt and NL-7nt/AP-1 we again generated latently infected T 16 
cells using J2574 reporter T cells.  In the resulting T cell clones, no differences in response to 17 
stimulation with PMA were observed.  As shown in Figure 6D, PIMi IV prevented reactivation of 18 
latent HIV-1 NL4-3wt infection in J2574 cells, but PIMi IV had no tangible inhibitory effect on 19 
PMA-induced reactivation of latent NL-7nt/AP-1 infection.  To the best of our knowledge, this is 20 
the first time that the activity of a kinase inhibitor that prevents HIV-1 reactivation can be 21 
functionally correlated to a specific transcription factor-binding motif in the HIV-1 LTR and 22 
provides additional support for the idea that latent HIV-1 infection is a transcription factor 23 
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 20 
the observed selectivity of the inhibitor for various cytokine promoters, where PIMi IV could act 1 
as an activator, an inhibitor, or without any effect on induced gene expression (Figure 4).   2 
It is important to appreciate that while we refer to an AP-1 motif and have previously 3 
provided experimental evidence that AP-1 factor binding affinity is altered by these mutations 4 
(12), the respective LTR region is also targeted by other transcription factors.  Among others, 5 
we have previously described a MARE half-site that overlaps with this sequence and to which c-6 
maf can bind (43).  Thus, while these data link the PIMi IV effect to the LTR nucleotide 7 
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Eradication of the latent viral reservoir will be an essential component of a curative 3 
therapy for HIV-1 infection.  The identification of a means to safely trigger system-wide 4 
reactivation of latent infection events is considered the crucial first step to achieve this goal.  A 5 
complete and detailed understanding of the different levels of molecular control that govern 6 
latent HIV-1 infection will be essential to develop such therapeutic strategies.  To this end, we 7 
have recently added to the list of molecular mechanisms controlling latent HIV-1 infection when 8 
we demonstrated that kinase control mechanisms suppress HIV-1 reactivation despite high 9 
levels of induced NF-κB activity (11).  Since 2000, about 20 drugs targeting kinases were FDA 10 
approved for a variety of diseases (for review see (44)) and the number of kinase-targeting 11 
drugs in the industry pipeline is rapidly growing. A gatekeeper kinase network that controls 12 
latent HIV-1 infection should thus be an attractive druggable target to trigger HIV-1 reactivation.  13 
Here we expand the concept that kinase control is a crucial part of HIV-1 latency control 14 
by demonstrating that latently HIV-1 infected T cells exhibit an altered baseline kinase activity 15 
profile relative to non-infected T cells and that some of these altered kinases, as exemplified by 16 
PIM-1, can be pharmacologically or genetically targeted to alter HIV-1 latency control.   17 
Availability of PIM-1, which by kinome profiling was identified as the top altered kinase in 18 
latently infected cells, was found to be a prerequisite to trigger latent HIV- 1 infection.  The role 19 
of PIM-1 in HIV-1 reactivation was confirmed using pharmacologic inhibitors, shRNA-induced 20 
knock down, and PIM-1 overexpression.  The finding was confirmed in primary CD4 T cells, 21 
where PIMi IV inhibited CD3/CD28 induced reactivation of latent HIV-1 infection. 22 
PIM-1 is an autophosphorylating serine/threonine kinase that is primarily regulated at the 23 
protein expression level.  Its expression has been reported to be regulated by cytokines such as 24 
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 22 
often overexpressed in immortalized cell lines, PIM-1 is not expressed in resting primary T cells, 1 
but its expression is rapidly induced after receptor cross-linking with anti-CD3 mAbs (46).  Once 2 
induced, PIM-1 has been described to phosphorylate NF-κB RelA/p65 at Ser276, thereby 3 
preventing NF-κB’s ubiquitin-mediated proteolysis (47).  PIM-1 has also been described to 4 
physically interact with NFATc1 and to phosphorylate NFATc1 in vitro on several serine 5 
residues (48).  PIM-1 was found to enhance NFATc1-dependent transactivation and IL-2 6 
production in Jurkat T cells, while kinase-deficient PIM-1 mutants acted as dominant negative 7 
inhibitors.  NFAT, in turn, has been described early on to interact with the HIV-1 LTR (49-51) 8 
and has been shown to augment LTR transcription via binding to the dual proximal NF-κB sites 9 
(43, 52-54).  NFAT further has been reported to be required for viral reactivation from latency in 10 
primary T cells (7).  How PIM-1 exactly acts to control HIV-1 reactivation at the transcription 11 
factor level remains to be elucidated. 12 
Beyond the specific effect of PIMi IV on HIV-1 reactivation, our findings have 13 
implications for our understanding of latent HIV-1 infection.  First, following our recent report that 14 
the JNK inhibitor AS601245 prevents reactivation of latent HIV-1 infection despite the efficient 15 
induction of NF-κB activity, PIMi IV is the second kinase inhibitor that we identify as capable of 16 
preventing HIV-1 reactivation by superseding the effect of NF-κB activity on latent HIV-1 17 
infection.  The data thus expand the concept that a kinase network is a major component of 18 
HIV-1 latency control. 19 
The second conclusion concerns the question at what molecular level PIM-1 kinase 20 
exerts its control activity on latent HIV-1 infection.  Kinases could affect many molecular 21 
mechanisms suggested to control latent HIV-1 infection. Kinase inhibitors may interfere with 22 
processes involved in histone/chromatin modifications reported to be essential for HIV-1 latency 23 
or alter the availability/activity of downstream transcription factors that are essential for HIV-1 24 
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 23 
sequence of the AP-1 motif in the CD28RE of the LTR suggests that the gatekeeper kinase 1 
network likely exerts its downstream control of latent HIV-1 infection through the latter 2 
mechanism.  3 
To explain that the 2 nt change in the LTR of NL-7nt/AP-1, which deprives PIMi IV of its 4 
inhibitory effect on HIV-1 reactivation, would interfere with mechanisms that affect histone 5 
modifications, nucleosome formation, nucleosome repositioning or chromatin structure at the 6 
latent LTR, one would have to assume that regulatory mechanisms involving histone or 7 
chromatin modifications act fundamentally different on latent NL43wt infection than on 8 
NL7nt/AP-1 infection based on a 2 nt mutation that was derived from a prototypic HIV-1 subtype 9 
A LTR sequence.  In extension, this would mean that the principal mechanisms governing HIV-1 10 
latency would change as a function of the LTR nucleotide sequence.  Given the uniform 11 
establishment of latent HIV-1 reservoirs in all patients tested to date on one hand, and on the 12 
other hand the sequence diversity of HIV-1 LTRs, this seems unlikely.  13 
The same considerations hold for a possible effect of PIMi IV on components of the 14 
paused RNAP II machinery at the latent LTR and its transition into active elongation following 15 
stimulation.  RNAP II complex formation, P-TEFb release from its inactive complex with HEXIM-16 
1, and availability of general transcription factors such as TFIIH could only be the target of 17 
PIMi IV when it is assumed that latent NL4-3wt infection at the level of RNAP II pausing, release 18 
or elongation is regulated in a fundamentally different manner than NL-7nt/AP-1 latency.  To this 19 
end it is important to appreciate that even the TATA-box, the TAR element, or the 20 
polyadenylation signal in the NL4-3 and the NL-7nt/AP-1 LTR are identical. Thus, while effects 21 
on histone composition, chromatin alterations or RNAP II pausing are not excluded by our data, 22 
the most likely explanation of our findings should be that PIMi IV, or for that matter changes in 23 
PIM expression by PIM-1 overexpression or knockdown, affect the availability of transcription 24 
factors that bind to the AP-1 motif in the HIV-1 LTRs.There are different possibilities of how this 25 
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factor composition as to favor binding of alternative transcription factors to the 7nt/AP-1 site, but 1 
not the wt AP-1 motif (Figure 6A).  However, more likely, based on our data, PIMi IV may simply 2 
incompletely inhibit the activation or availability of one specific transcription factor. In this 3 
situation, higher binding affinity of the 7nt/AP-1 motif for the residual transcription factor activity 4 
would be sufficient to allow for reactivation of latent NL-7nt/AP-1 infection, but not for latent 5 
NL4-3wt infection. 6 
While we demonstrate that there are differences in the kinases activity profile of 7 
uninfected and latently infected T cells, and these findings can be transferred to latently HIV-1 8 
infected primary T cells, it remains unclear at the time why exactly these kinases are altered. It 9 
is conceivable that the observed phenotypic changes of the kinome profile are reflective of a 10 
cellular anti-viral response program, or are part of a viral program that alters cells to favor viral 11 
replication.  Phenotypic (epigenetic) changes of host cells following infection or even just 12 
exposure to viruses have been recently reported in different systems (55).  Specifically, for 13 
latent HIV-1 infection, a recent paper provides evidence that CD2 expression levels could be 14 
one in vivo biomarker of latent HIV-1 infection (56).  Changes in the kinome profile would be the 15 
intracellular reflection of such protein expression changes.   16 
In summary, the data thus confirm the presence of a gatekeeper kinase network that 17 
controls latent HIV-1 infection in T cells and provide experimental evidence that control is 18 
achieved at the level of restriction of specific transcription factor engagement of the HIV-1 LTR.  19 
As kinase control of latent HIV-1 infection supersedes NF-κB activity, and as the data reveal 20 
that latently infected T cells phenotypically differ from uninfected T cells, our results suggest that 21 
by targeting the relevant kinase control mechanisms, it may be possible to dissociate HIV-1 22 
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 25 
Beyond the molecular biology, the immediately apparent link between kinome analysis 1 
data and pharmacological or genetic perturbation data suggests that kinome profiling, which is 2 
now an established tool in cancer research, can also become a powerful tool to help identify the 3 
protein-protein interactions that control HIV-1 latency and guide the development of novel 4 
targeted intervention strategies.  In this setting, as we begin to better understand the underlying 5 
interactions of HIV-1 latency control, kinase antagonist or agonists that can act to transition 6 
latent HIV-1 infection into an active expression state will become an important part of future 7 
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TABLE 1 1 
 2 
Table 1: Ranking of PIM kinases based on kinomically identified kinases with increased activity in latently HIV-1 
infected Jurkat T cells relative to control Jurkat T cells. 
 CA5 EF7 J89GFP 
 Rank ratio score Rank ratio score Rank ratio score 
PIM1 Kinase 6 38.2 Kinase 4 40.9 Kinase 1 56.3 
PIM2 Kinase 7 38.2 NR - Kinase 5 37.5 
PIM3 Kinase 8 38.2 Kinase 6 40.9 Kinase 2 56.3 
NR: not ranked 3 
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FIGURE LEGENDS 1 
 2 
Figure 1:  Shortest paths diagram for kinase control of latent HIV-1 infection. Source 3 
Uniprot IDs for phosphopeptides found increased in three analyzed latently HIV-1 infected T cell 4 
lines (CA5, EF7, J89GFP) over parental Jurkat T cells along with the Uniprot ID for PIM1 were 5 
uploaded to GeneGo MetaCore (Thomson Reuters) as seed nodes for Network analysis using 6 
Dijkstra's Shortest Paths algorithm to identify directed interactions among these seed nodes. 7 
PIM1's interactions were selected (highlighted paths) with PIM1 canonical pathway 8 
interactions highlighted in light blue, and other PIM1 interactions highlighted in yellow. NF-κB 9 
was the most interconnected node and its interaction with PIM-1 is highlighted in dark blue. 10 
 11 
 12 
Figure 2:  PIM-1 inhibitor IV prevents activation induced HIV-1 reactivation.  (A) Latently 13 
HIV-1 infected CA5 reporter T cells were stimulated with the phorbol ester PMA (3 ng/ml) in the 14 
presence or absence of PIMi IV (10 µM) and reactivation was measured as the percentage of 15 
GFP-positive cells using flow cytometric analysis.  (B) PIMi IV was titrated on CA5 T cells 16 
against TNF-α (10 ng/ml) or PMA (3 ng/ml) as HIV-1 reactivating agents.  The level of HIV-1 17 
reactivation was determined as %GFP-positive cells using flow cytometric analysis and plotted 18 
over the PIMi IV concentration. CA5 T cells were preincubated for 6 hours with PIMi IV prior to 19 
triggering HIV-1 reactivation.  (C) PIMi II was titrated on CA5 T cells against TNF-α (10 ng/ml) or 20 
PMA (3 ng/ml) as HIV-1 reactivating agents.  The level of HIV-1 reactivation was determined as 21 
%GFP-positive cells using flow cytometric analysis and plotted over the PIMi II concentration. 22 
CA5 T cells were preincubated for 18 hours with PIMi II prior to triggering reactivation.  (D) 23 
PIMi IV was titrated on chronically actively HIV-1 infected JNLG T cells.  GFP mean channel 24 
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HIV-1 expression. (E) The latently HIV-1 infected T cell lines CA5 and EF7 were retrovirally 1 
transduced to overexpress PIM-1 protein.  Following retroviral transduction, bryostatin, an anti-2 
cancer drug candidate that triggers PKC/NF-κB activation was titrated on CA5-PIM or EF7-PIM 3 
cells (PIM) and the level of HIV-1 reactivation as measured by GFP expression was compared 4 
to the parental cells (control). (F) PIM-1 expression in CA5 T cells was knocked down using two 5 
different anti-PIM-1 shRNA constructs (shPIM#10, shPIM#22) and PIM-1 shRNA-transduced 6 
clones were generated.  For an unbiased, representative cross-section of CA5-shPIM#22 cell 7 
clones TNF-α was then titrated on either control CA5 T cells (black symbols), a population of 8 
CA5 T cells that were transduced with a scrambled shRNA and then puromycin selected (large 9 
gray triangles) and the various generated PIM-1 shRNA transduced clones (gray symbols/lines; 10 
all left panel) and determined as % GFP-positive cells as a surrogate marker of HIV-1 11 
reactivation.  The effect of PIM-1 knock-down on concentration dependent TNF-α mediated 12 
HIV-1 reactivation was detailed for four CA5-shPIM#10 cell clones (middle panel) and 13 
achievable HIV-1 reactivation levels (percentage of GFP-positive cells) were correlated with 14 
PIM-1 expression as determined by western blot for PIM-1 (right panel). The numbers over the 15 
insert showing the western blot data describe the band intensities [A.U.] for PIM-1 expression. 16 
 17 
 18 
Figure 3:  PIMi IV inhibits HIV-1 reactivation in latently HIV-1 infected primary T cells.  (A) 19 
Latently HIV-1 infected cultured central memory T cells were prepared from primary naïve T 20 
cells as previously described (7, 27).  Active infection events were indicated by GFP 21 
fluorescence (Donor 1) or by p24 stain (Donor 2).  Over low-level background infection (control), 22 
HIV-1 reactivation was triggered using a CD3/CD28 mAb combination.  Cyclosporin A (CsA) 23 
prevented and PIMi IV markedly inhibited CD3/CD28 mAb induced reactivation.  The 24 
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 30 
CD3/CD28 mAb-mediated T cell activation, primary T cells were left untreated (control) or 1 
CD3/CD28 mAb stimulated in the absence or presence of 10 µM PIMi IV.  T cell activation was 2 
determined as the induction of CD25/IL-2 receptor-α chain expression by flow cytometric 3 
analysis.  The experiment is representative of a total of 4 healthy donors tested. 4 
 5 
Figure 4: PIMi IV effects on activation induced cytokine gene expression.  In the absence 6 
or presence of PIMi IV (10 µM), CD4 T cells from three healthy donors were stimulated with 7 
PHA-L (10 µg/ml).  24h post stimulation culture supernatants were harvested and analyzed for 8 
the presence of IL-2, IL-4, IL-6, IL-8, IL-17, and IFN-γ using multiplex analysis.   9 
 10 
 11 
Figure 5:  PIMi IV prevents reactivation of latent HIV-1 infection despite high levels of 12 
TNF-α  induced NF-κB activity.  (A) CA5 T cells were stimulated with TNF-α (10 ng/ml)  in the 13 
absence (control) or presence of PIMi IV (10 µM).  Cells were harvested at the indicated time 14 
points, nuclear extracts were prepared, and NF-κB p50 and p65 activity was measured using 15 
TransAM assays. (B) Maximum initial NF-κB activation achieved in the absence or presence of 16 
PIMi IV (10 µM) one hour post TNF-α activation was determined in 3 independent experiments. 17 
The p-values (Student’s T-test) describing the significance of possible differences between the 18 
stimulated control conditions (TNF) and the PIMi IV treated TNF-α-stimulated conditions 19 
(PIMi/TNF) are shown.  (C) TNF-α induced HIV-1 reactivation levels in CA5 T cells in the 20 
absence or presence of PIMi IV as used in the kinetic NF-κB activation experiments depicted in 21 
(A).  (D) In the absence or presence of PIMi IV, CA5 T cells were stimulated with TNF-α and 22 
cells were harvested at the indicated time points.  Western blots were performed to determine 23 
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were stripped and probed for tubulin expression (shown for activated CA5 T cells treated with 1 
PIMi IV). 2 
 3 
 4 
Figure 6: PIMi IV prevents reactivation of latent HIV-1 in a LTR sequence-dependent 5 
manner.  HIV-1 LAI-B and LAI-A, two viruses that are syngeneic with the exception of the 6 
extended core/enhancer region of the LTR (from -1 to -147nt with respect to the transcriptional 7 
start site) were used to generate latently infected T cells. (A) Schematic representation of the 8 
viral LTR indicating the extended core/enhancer region that is representative of a prototypic 9 
subtype A sequence in LAI-A and representative of a prototypic subtype B region in LAI-B.  The 10 
nucleotide sequences represent the CD28RE of NL4-3 and NL-7nt/AP-1 that were used in (D).  11 
AP-1 motifs are printed in bold capital letters, whereas NF-κB sites are indicated in capital 12 
letters only.  (B) Effect of increasing amounts of PIMi IV on PMA (3 ng/ml) induced HIV-1 13 
reactivation of a latent LAI-B infection (Jlat-B cells) and latent LAI-A infection (Jlat-A cells).  (C) 14 
Increasing concentrations of PIMi IV inhibited HIV-1 reactivation in a J2574 reporter T cell 15 
population holding ~4% latently LAI-B infected cells (gray circles), but only had a minor 16 
inhibitory effect on HIV-1 reactivation in a J2574 reporter T cell population holding ~10% latent 17 
LAI-A infection events (left panel).  For better comparison of the inhibitory effect of PIMi IV on 18 
the latently LAI-A and LAI-B infection in the cell populations, results were normalized to 19 
maximum achievable reactivation levels and plotted as relative level of reactivation, normalized 20 
for active background infection (0.8% for LAI-B; 1.1% for LAI-A) (right panel).  (D) Using NL-21 
7nt/AP-1, a virus that is altered in 2 nucleotides relative to NL4-3wt to provide a subtype A 22 
prototypic AP-1 site in the CD28RE, we generated a latently infected J2574 reporter T cell 23 
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circles), while it efficiently inhibited HIV-1 reactivation of latent HIV-1 NL4-3wt infection (gray 1 
triangles).  All results represent the mean ± standard deviation of 3 independent experiments. 2 
 3 
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